Samchully and TechniKrom Expands cGMP Oligonucleotide Manufacturing Systems
News Jul 10, 2007
Under terms of the agreement TechniKrom will offer its engineering, fabrication, and qualification services to supply 100-mmol scale cGMP oligosynthesis and HPLC equipment to Samchully.
“We are excited to select TechniKrom, well-known in the industry for supplying the highest quality HPLC systems and large scale oligosynthesizers; this will be a key component of our expansion project, targeting clients who are looking for mid-scale siRNA and aptamer supply; we believe it supports our continuing efforts to become a sole “integrated supplier” to drive down the costs of manufacturing for oligos, complementing our nucleoside monomer capability,” said Samchully Director of Business Development, Dr. Moon-Hee Kim.
TechniKrom has experienced significant growth in its oligonucleotide equipment business since 2004. “We are pleased to partner with an up and coming company like Samchully, who has proven-track record in nucleoside manufacturing and scale-up, to enable them to meet the growing demand for large scale oligonucleotide manufacturing,” said TechniKrom President, CEO and founder, Lou Bellafiore.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.